Next Generation Humanized Mice for AML and NK Cell Therapy Testing
Join Amy Wesa, PhD, director of Immuno-Oncology Research at Champions Oncology Inc. discussing the latest advances in human immune system mouse models for oncology therapeutics and more!
To develop the most successful novel agents for cancer, researchers require preclinical models that fundamentally epitomize patient populations to enable predictive outcomes. Patient-derived models represent a considerable advantage over traditional models of cancer to expedite drug development. In this webinar, Amy Wesa, PhD, will discuss:
- How complementing these translational PDX models with the introduction of human immune cells is driving the next generation of patient-derived models
- The latest advances in human immune system mouse models for oncology therapeutics
- The power of primary patient-derived models for acute myeloid leukemia (AML)
- Novel methods for evaluating natural killer (NK) cell therapeutics of cancer in humanized mice